AAPL289.16+7.42 (+2.63%) ▲|ABBV252.55-1.76 (-0.69%) ▼|ABT91.62-1.09 (-1.18%) ▼|ACN123.89-0.85 (-0.68%) ▼|ADBE202.40-4.04 (-1.95%) ▼|AMAT730.21+35.57 (+5.12%) ▲|AMD572.95+33.46 (+6.20%) ▲|AMGN359.32-1.23 (-0.34%) ▼|AMT164.00-4.67 (-2.77%) ▼|AMZN239.47-0.67 (-0.28%) ▼|AVGO375.32+2.87 (+0.77%) ▲|AXP337.93-2.95 (-0.87%) ▼|BA216.73+2.04 (+0.95%) ▲|BAC57.02-0.87 (-1.49%) ▼|BKNG179.97-2.44 (-1.34%) ▼|BLK961.93+11.76 (+1.24%) ▲|BMY57.76-0.81 (-1.37%) ▼|BNY144.96+1.16 (+0.81%) ▲|BRK-B496.56+0.56 (+0.11%) ▲|C140.00-2.49 (-1.75%) ▼|CAT1,063.07+29.88 (+2.89%) ▲|CL91.95-0.46 (-0.49%) ▼|CMCSA24.54+0.32 (+1.30%) ▲|COF200.47-1.81 (-0.89%) ▼|COP104.36+0.16 (+0.15%) ▲|COST936.72-9.96 (-1.05%) ▼|CRM154.85-3.08 (-1.95%) ▼|CSCO118.13+0.43 (+0.36%) ▲|CVS103.39-0.20 (-0.19%) ▼|CVX167.77-0.70 (-0.42%) ▼|DE627.71+2.70 (+0.43%) ▲|DHR190.17-2.61 (-1.35%) ▼|DIS96.82-1.07 (-1.09%) ▼|DUK127.75-0.58 (-0.45%) ▼|EMR143.17+0.35 (+0.25%) ▲|FDX310.30-15.10 (-4.64%) ▼|GD352.36+4.29 (+1.23%) ▲|GE372.14-1.57 (-0.42%) ▼|GEV1,136.11+33.60 (+3.05%) ▲|GILD125.94-0.40 (-0.31%) ▼|GM76.24-1.10 (-1.42%) ▼|GOOG353.23+1.95 (+0.56%) ▲|GOOGL356.25+2.60 (+0.74%) ▲|GS1,012.12-8.09 (-0.79%) ▼|HD351.68+0.87 (+0.25%) ▲|HON223.56-4.24 (-1.86%) ▼|IBM277.94-0.06 (-0.02%) ▼|INTC139.67+7.95 (+6.04%) ▲|INTU261.85-4.55 (-1.71%) ▼|ISRG402.03-3.94 (-0.97%) ▼|JNJ255.29-3.23 (-1.25%) ▼|JPM327.51-1.88 (-0.57%) ▼|KO82.02-0.63 (-0.76%) ▼|LIN519.52+8.46 (+1.65%) ▲|LLY1,209.02-20.91 (-1.70%) ▼|LMT505.63+3.56 (+0.71%) ▲|LOW219.21-0.44 (-0.20%) ▼|LRCX426.47+15.56 (+3.79%) ▲|MA511.55+1.91 (+0.37%) ▲|MCD269.20+2.02 (+0.76%) ▲|MDLZ58.98-1.17 (-1.95%) ▼|MDT79.32-1.62 (-2.00%) ▼|META556.23-6.37 (-1.13%) ▼|MMM162.36-0.08 (-0.05%) ▼|MO72.57-1.48 (-2.00%) ▼|MRK128.35-1.03 (-0.80%) ▼|MS209.12-2.60 (-1.23%) ▼|MSFT370.29+1.72 (+0.47%) ▲|MU1,143.41-1.88 (-0.16%) ▼|NEE88.15-0.51 (-0.58%) ▼|NFLX72.68-1.11 (-1.50%) ▼|NKE41.04-0.45 (-1.07%) ▼|NOW97.61-2.37 (-2.37%) ▼|NVDA198.38+3.41 (+1.75%) ▲|ORCL145.41-2.36 (-1.59%) ▼|PEP136.34-2.34 (-1.69%) ▼|PFE24.08-0.29 (-1.19%) ▼|PG145.79-2.67 (-1.80%) ▼|PLTR116.87+1.17 (+1.01%) ▲|PM179.75-3.13 (-1.71%) ▼|QCOM186.61-2.11 (-1.12%) ▼|RTX188.55+1.22 (+0.65%) ▲|SBUX102.88-1.18 (-1.13%) ▼|SCHW92.47+1.92 (+2.12%) ▲|SO96.40-0.36 (-0.37%) ▼|SPG224.92-2.65 (-1.16%) ▼|T20.90-0.93 (-4.24%) ▼|TMO500.05-6.37 (-1.26%) ▼|TMUS168.85-5.12 (-2.94%) ▼|TSLA416.37+4.53 (+1.10%) ▲|TXN294.38+8.90 (+3.12%) ▲|UBER73.38-2.12 (-2.81%) ▼|UNH416.48-3.34 (-0.80%) ▼|UNP271.91-0.80 (-0.29%) ▼|UPS106.37-1.64 (-1.52%) ▼|USB60.54-0.22 (-0.36%) ▼|V342.68+1.03 (+0.30%) ▲|VZ42.78-1.32 (-2.99%) ▼|WFC82.82-0.69 (-0.83%) ▼|WMT113.63-0.98 (-0.85%) ▼|XOM136.10+0.04 (+0.03%) ▲|AAPL289.16+7.42 (+2.63%) ▲|ABBV252.55-1.76 (-0.69%) ▼|ABT91.62-1.09 (-1.18%) ▼|ACN123.89-0.85 (-0.68%) ▼|ADBE202.40-4.04 (-1.95%) ▼|AMAT730.21+35.57 (+5.12%) ▲|AMD572.95+33.46 (+6.20%) ▲|AMGN359.32-1.23 (-0.34%) ▼|AMT164.00-4.67 (-2.77%) ▼|AMZN239.47-0.67 (-0.28%) ▼|AVGO375.32+2.87 (+0.77%) ▲|AXP337.93-2.95 (-0.87%) ▼|BA216.73+2.04 (+0.95%) ▲|BAC57.02-0.87 (-1.49%) ▼|BKNG179.97-2.44 (-1.34%) ▼|BLK961.93+11.76 (+1.24%) ▲|BMY57.76-0.81 (-1.37%) ▼|BNY144.96+1.16 (+0.81%) ▲|BRK-B496.56+0.56 (+0.11%) ▲|C140.00-2.49 (-1.75%) ▼|CAT1,063.07+29.88 (+2.89%) ▲|CL91.95-0.46 (-0.49%) ▼|CMCSA24.54+0.32 (+1.30%) ▲|COF200.47-1.81 (-0.89%) ▼|COP104.36+0.16 (+0.15%) ▲|COST936.72-9.96 (-1.05%) ▼|CRM154.85-3.08 (-1.95%) ▼|CSCO118.13+0.43 (+0.36%) ▲|CVS103.39-0.20 (-0.19%) ▼|CVX167.77-0.70 (-0.42%) ▼|DE627.71+2.70 (+0.43%) ▲|DHR190.17-2.61 (-1.35%) ▼|DIS96.82-1.07 (-1.09%) ▼|DUK127.75-0.58 (-0.45%) ▼|EMR143.17+0.35 (+0.25%) ▲|FDX310.30-15.10 (-4.64%) ▼|GD352.36+4.29 (+1.23%) ▲|GE372.14-1.57 (-0.42%) ▼|GEV1,136.11+33.60 (+3.05%) ▲|GILD125.94-0.40 (-0.31%) ▼|GM76.24-1.10 (-1.42%) ▼|GOOG353.23+1.95 (+0.56%) ▲|GOOGL356.25+2.60 (+0.74%) ▲|GS1,012.12-8.09 (-0.79%) ▼|HD351.68+0.87 (+0.25%) ▲|HON223.56-4.24 (-1.86%) ▼|IBM277.94-0.06 (-0.02%) ▼|INTC139.67+7.95 (+6.04%) ▲|INTU261.85-4.55 (-1.71%) ▼|ISRG402.03-3.94 (-0.97%) ▼|JNJ255.29-3.23 (-1.25%) ▼|JPM327.51-1.88 (-0.57%) ▼|KO82.02-0.63 (-0.76%) ▼|LIN519.52+8.46 (+1.65%) ▲|LLY1,209.02-20.91 (-1.70%) ▼|LMT505.63+3.56 (+0.71%) ▲|LOW219.21-0.44 (-0.20%) ▼|LRCX426.47+15.56 (+3.79%) ▲|MA511.55+1.91 (+0.37%) ▲|MCD269.20+2.02 (+0.76%) ▲|MDLZ58.98-1.17 (-1.95%) ▼|MDT79.32-1.62 (-2.00%) ▼|META556.23-6.37 (-1.13%) ▼|MMM162.36-0.08 (-0.05%) ▼|MO72.57-1.48 (-2.00%) ▼|MRK128.35-1.03 (-0.80%) ▼|MS209.12-2.60 (-1.23%) ▼|MSFT370.29+1.72 (+0.47%) ▲|MU1,143.41-1.88 (-0.16%) ▼|NEE88.15-0.51 (-0.58%) ▼|NFLX72.68-1.11 (-1.50%) ▼|NKE41.04-0.45 (-1.07%) ▼|NOW97.61-2.37 (-2.37%) ▼|NVDA198.38+3.41 (+1.75%) ▲|ORCL145.41-2.36 (-1.59%) ▼|PEP136.34-2.34 (-1.69%) ▼|PFE24.08-0.29 (-1.19%) ▼|PG145.79-2.67 (-1.80%) ▼|PLTR116.87+1.17 (+1.01%) ▲|PM179.75-3.13 (-1.71%) ▼|QCOM186.61-2.11 (-1.12%) ▼|RTX188.55+1.22 (+0.65%) ▲|SBUX102.88-1.18 (-1.13%) ▼|SCHW92.47+1.92 (+2.12%) ▲|SO96.40-0.36 (-0.37%) ▼|SPG224.92-2.65 (-1.16%) ▼|T20.90-0.93 (-4.24%) ▼|TMO500.05-6.37 (-1.26%) ▼|TMUS168.85-5.12 (-2.94%) ▼|TSLA416.37+4.53 (+1.10%) ▲|TXN294.38+8.90 (+3.12%) ▲|UBER73.38-2.12 (-2.81%) ▼|UNH416.48-3.34 (-0.80%) ▼|UNP271.91-0.80 (-0.29%) ▼|UPS106.37-1.64 (-1.52%) ▼|USB60.54-0.22 (-0.36%) ▼|V342.68+1.03 (+0.30%) ▲|VZ42.78-1.32 (-2.99%) ▼|WFC82.82-0.69 (-0.83%) ▼|WMT113.63-0.98 (-0.85%) ▼|XOM136.10+0.04 (+0.03%) ▲|
28.8 C
New York
Tuesday, June 30, 2026

Tag: patients

Everest Medicines Showcases Breakthroughs in Proprietary AI-Powered mRNA Platform at 2025 R&D Day Held in Shanghai

SHANGHAI, July 4, 2025 /PRNewswire/ -- Everest Medicines (HKEX: 1952.HK), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative...

Kexing Biopharm Makes Its Debut at CPHI 2025, Followed by the 2025 International Pharmaceutical Cooperation High-End Forum, One of the Kexing Biopharm’s Series of...

SHENZHEN, China, July 4, 2025 /PRNewswire/ -- Recently, Kexing Biopharm made a remarkable appearance at CPHI & PMEC China 2025 and successfully organized the...

Nxera Pharma to Receive US$4.8 Million in Milestone Payments Following Centessa’s Initiation of Clinical Development of ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist

Tokyo, Japan and Cambridge, UK, 4 July 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that it will receive US$4.8 million in milestone payments from Centessa Pharmaceuticals pursuant to its research collaboration with Centessa. The milestones were achieved as Centessa initiated clinical development of ORX142, its second novel orexin receptor 2 (OX2R) agonist, following the recent clearance of an Investigational New Drug (IND) application by the US Food and Drug Administration (FDA) for a Phase 1 clinical study of ORX142 in healthy volunteers. (click here).

Strüngmann Award Honors Araris Biotech Founding Team as 2025 Winner

Munich, Germany, July 04, 2025 – The Strüngmann Award selection committee today announced that Dragan Grabulovski, Ph.D., Philipp Spycher, Ph.D., and Isabella Attinger-Toller, Ph.D., the founders of Araris Biotech, have been honored as this year’s winners. The award aims to support outstanding entrepreneurial and scientific achievements, as well as ground-breaking ideas in the life sciences industry. Araris Biotech’s founding team distinguished itself not only by developing of a novel technology in the antibody-drug conjugates (ADCs) field, but also by successfully validating this innovation through partnerships and a preclinical exit. This new drug class has the potential to significantly advance the development of targeted cancer therapies, thereby delivering added value for people living with cancer worldwide.

The Villages Health (“TVH”) Announces Strategic Restructuring and Agreement to be Acquired by CenterWell

ORLANDO, Fla., July 3, 2025 /PRNewswire/ -- The Villages Health ("TVH"), the trusted healthcare system for The Villages retirement community in Florida, today announced...

Brii Biosciences Announces Licensing Agreement with Joincare Group for Rights to BRII-693 in Greater China

Joincare Group to lead the clinical development and commercialization of BRII-693 in Greater ChinaBrii Biosciences retains ex-Greater China rights to address the global antimicrobial...

Brii Biosciences Announces Licensing Agreement with Joincare Group for Rights to BRII-693 in Greater China

Joincare Group to lead the clinical development and commercialization of BRII-693 in Greater ChinaBrii Biosciences retains ex-Greater China rights to address the global antimicrobial...

Remote Pharmacy Releases 2025 Availability Update on GLP-1 Weight Loss Solutions and Consumer Interest in Semaglutide & Tirzepatide

In this 2025 availability update, Remote Pharmacy highlights the expanded access to non-branded GLP-1-based weight management options, including semaglutide and tirzepatide compounds. The release explores the evolving role of compounded therapeutics, shifts in consumer behavior toward remote prescribing, and how new formulations align with the growing interest in safe, physician-directed care for weight management.
In this 2025 availability update, Remote Pharmacy highlights the expanded access to non-branded GLP-1-based weight management options, including semaglutide and tirzepatide compounds. The release explores the evolving role of compounded therapeutics, shifts in consumer behavior toward remote prescribing, and how new formulations align with the growing interest in safe, physician-directed care for weight management.

ReCerf Receives its CE Mark, Advancing Access to Ceramic Hip Resurfacing Across Europe

LEATHERHEAD, England, July 4, 2025 /PRNewswire/ -- MatOrtho® is proud to announce that the ReCerf® Hip Resurfacing Arthroplasty (HRA) has received its CE mark,...

AAPA Statement on Passage of the “Big Beautiful Bill”

ALEXANDRIA, Va., July 3, 2025 /PRNewswire/ -- The American Academy of Physician Associates (AAPA) President and Chair of the Board, Todd Pickard, DMSc, PA-C,...

GPRC5D-directed Therapies Market is Anticipated to Gain Momentum During the Forecast Period (2025-2034) Owing to Unmet Need in Multiple Myeloma | DelveInsight

The GPRC5D-directed therapies market is witnessing robust growth, driven by the high unmet need in relapsed/refractory multiple myeloma. Innovative modalities like CAR-T cells, bispecific...

GPRC5D-directed Therapies Market is Anticipated to Gain Momentum During the Forecast Period (2025-2034) Owing to Unmet Need in Multiple Myeloma | DelveInsight

The GPRC5D-directed therapies market is witnessing robust growth, driven by the high unmet need in relapsed/refractory multiple myeloma. Innovative modalities like CAR-T cells, bispecific...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsPatients